ERCC1 AND OTHER MARKERS FOR STRATIFICATION OF NON-SMALL CELL LUNG CANCER PATIENTS

摘要

Proteomics data are employed to predict treatment outcome for cisplatin/pemetrexed therapy of NSCLC. Notably, ERRC1 can be used as a binary marker where protein presence or absence is measured by mass spectroscopy, and additional proteins may serve as further predictive markers, particularly for prediction of PFS.